Not each FTSE 100 inventory decide is usually a winner. I maintain round 20 blue-chips and two have suffered: mining big Glencore (LSE: GLEN) and prescription drugs titan GSK (LSE: GSK).

Their shares are down 8% and 12%, respectively, over 12 months. Personally, I’m sitting on paper losses of 16% and 19%, regardless of choosing up just a few dividends and sure, it hurts.

Whereas the declines are disappointing, I’m hanging on within the hope of a turnaround. So what are the possibilities?

Can the Glencore share price rebound?

As one of many world’s largest miners and merchants, Glencore’s closely uncovered to the risky costs of key assets like coal, copper, and zinc.

That was fantastic when China was posting double-digit GDP progress 12 months after 12 months, whereas gobbling up 60% of the worldwide provide of metals and minerals. These days are over and as one Beijing stimulus bundle after one other underwhelms, we are able to’t assume they’ll come again.

Glencore additionally has to navigate the pivot in the direction of renewable power and a low-carbon future. Its substantial coal enterprise stays extremely worthwhile however is at odds with international decarbonisation objectives.

President Donald Trump’s mooted tariffs are one other concern. The Glencore share price jumped on Friday, together with the commodity sector usually, as Trump (for now at the least) adopted a much less strident stance. There’ll little doubt be additional twists to come back.

The shares look good worth buying and selling at 10.5 occasions earnings whereas its 2.6% yield could also be topped up by one-off dividends within the spring.

The 15 analysts providing one-year share price forecasts have produced a median goal of 493p. If right, that’s a bumper improve of virtually 30% from at the moment. I’d hate to overlook out if that occurs. In a famously cyclical sector, I’d be daft to promote when the shares are down.

Lengthy-term GSK buyers will be forgiven for feeling grumpy. The inventory’s down 18% on a decade in the past. And though buyers have acquired loads of dividends in that point, they’d have hoped for extra. As we speak’s 4.25% trailing yield’s strong however nonetheless under the 6% or in order that buyers used to anticipate.

GSK shares are down, however not out

Pouring cash into R&D as an alternative was supposed to spice up the pipeline and share price. It’s probably not occurred but. Spinning off client healthcare enterprise Haleon didn’t add a lot shine to the mothership both.

I believed the GSK share price would rebound final 12 months because it settled a US class motion case over heartburn treatment Zantac. The reduction was short-lived. And with Trump focusing on huge pharma, buyers have one other fear.

GSK shares are low cost, buying and selling at 8.8 occasions earnings, however there’s a lingering suspicion of a price entice right here.

The 17 analysts providing one-year share price forecasts have produced a median goal of 1,618p. If right, that’s a rise of virtually 19% from at the moment. Mixed with that yield, this might give me a complete return of 23%. I can’t see it occurring, however I’ll grasp on simply in case.

I might positively see Glencore rallying exhausting from right here. I believe GSK might be a protracted, gradual haul. I proceed to carry each however I actually ought to have purchased Nvidia.